Five of the world’s 15 largest pharmaceutical companies, including Pfizer Inc., promised seven-figure upfront payments each to venture-funded Ablexis LLC in a unique deal for a finely tuned transgenic mouse that could make it easier to discover and develop antibody drugs.
The companies each also will make eight-figure payments to Ablexis once the company, started in December and housed in the FibroGen building in San Francisco’s Mission Bay, delivers its AlivaMab mouse strains.
The companies each also will make eight-figure payments to Ablexis once the company, started in December and housed in the FibroGen building in San Francisco’s Mission Bay, delivers its AlivaMab mouse strains.
No comments:
Post a Comment